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Computationally supported development of small molecule inhibitors has successfully been applied to
protein tyrosine phosphatases in the past, revealing a number of cell-active compounds. Similar ap-
proaches have also been used to screen for small molecule inhibitors for the cancer-related phosphatases
of regenerating liver (PRL) family. Still, selective and cell-active compounds are of limited availability.
Since especially PRL-3 remains an attractive drug target due to its clear role in cancer metastasis, such
compounds are highly demanded. In this study, we investigated various virtual screening approaches for
their applicability to identify novel small molecule entities for PRL-3 as target. Biochemical evaluation of
purchasable compounds revealed ligand-based approaches as well suited for this target, compared to
docking-based techniques that did not perform well in this context. The best hit of this study, a 2-cyano-
2-ene-ester and hence a novel chemotype targeting the PRLs, was further optimized by a structure
eactivity-relationship (SAR) study, leading to a low micromolar PRL inhibitor with acceptable selectivity
over other protein tyrosine phosphatases. The compound is active in cells, as shown by its ability to
speciﬁcally revert PRL-3 induced cell migration, and exhibits similar effects on PRL-1 and PRL-2. It is
furthermore suitable for ﬂuorescence microscopy applications, and it is commercially available. These
features make it the only purchasable, cell-active and acceptably selective PRL inhibitor to date that can
be used in various cellular applications.
© 2014 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).elliferyl phosphate; DSP, dual
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Cellular signaling processes are tightly regulated through
phosphorylation and dephosphorylation of proteins and second
messenger molecules by the action of kinases and phosphatases,
respectively, thereby maintaining the correct function of cellular
life. A perturbation in these highly controlled regulation processes
can lead to the formation and progression of various diseases [1]. It
is therefore critical to identify small organic molecules that inhibit
unwanted hyperfunction of disease-promoting kinases and phos-
phatases; on the one hand to diminish disease progression through
drug development, on the other hand to gain a better under-
standing of the biological mechanisms behind these processes [1].
The phosphatases of regenerating liver (PRL)-1, PRL-2 and PRL-3
are of particular interest as drug targets, because these putative
oncogenes are strongly involved in cancer formation and progres-
sion [2]. Theywere shown to inﬂuence angiogenesis andmetastasisarticle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-
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PRL-2 and PRL-3 are highly overexpressed in various types of
cancer [3]. PRL-3 is especially found in liver metastasis rather than
the primary tumors [7], making it an important drug target as
cancer metastasis is the major cause for poor prognosis in cancer
due to the impossibility of surgery at this late state of disease [8,9].
Few normal functions of the PRL phosphatases are known: PRL-
1 is an immediate-early response gene in regenerating liver and
involved in cell differentiation, and the latter also appears to be the
case for PRL-3. Additionally, all three PRLs have been suggested to
regulate cell cycle progression [3]. The PRL phosphatases are
members of the cysteine-based dual-speciﬁcity group of phos-
phatases (DSPs), which belongs to the protein tyrosine phosphatase
(PTP) superfamily. Members of the DSPs not only are able to de-
phosphorylate phosphotyrosines like the classical PTPs but also to
hydrolyze phosphomonoesters of serines, threonines, and non-
protein substrates [10]. The sequence identities of PRLs compared
to other phosphatases are low, but very high among the members
of the PRL family. The PRLs are small (21 kDa), single domain pro-
teins. Uncommon compared to other DSPs, their active site is both
shallow and hydrophobic, allowing for the dephosphorylation of
phosphotyrosines, phosphoserines and phosphothreonines as well
as phosphoinositides (in the case of PRL-3) [3,8,11].
The development of inhibitors of the PRLs, and DSPs in general,
is difﬁcult. It is therefore not surprising that, despite their attractive
features as drug targets, a drug targeting a DSP has yet to be
approved. The challenge in developing phosphatase inhibitors as
drug leads lays in often-found drawbacks of limited selectivity and
poor pharmacokinetics [1]. This is due to the conserved active site
geometry of many DSPs, and their preference to bind negatively
charged entities [12]. In particular, ﬁnding selective active site in-
hibitors for one of the members of the PRL-family of phosphatases
is a delicate task, since although their active site architecture is
quite unique among phosphatases, they all share the shallow and
hydrophobic binding pocket, making it difﬁcult to ﬁnd small mol-
ecules being able to only bind to one of the three PRL members [3].
So far, the developed small molecule PRL-inhibitors are either not
selective when compared to other phosphatases, they do not show
selectivity amongst the PRL-family, or they simply were tested for
only one of the PRLs [13e19]. Selectivity within the PRL family may
not be necessary for a drug lead as they are all putative oncogenes,
but it is desirable to study their co-expression in cancers and po-
tential redundancy in their roles as these aspects still need to be
investigated in detail. The most potent cell-active inhibitor identi-
ﬁed to date is thienopyridone, with a reported IC50 of 173 nM for
PRL-1, 277 nM for PRL-2 and 128 nM for PRL-3 [17]. This compound,
however, is not commercially available for applications in PRL
biology research. Thienopyridone was found through high-
throughput screening. Other experimental approaches to discover
inhibitors included manual testing of single compounds based on
their known cellular effect [19].
Virtual screening is an attractive alternative to search for PRL
inhibitors. When a known ligand of the target is available, molec-
ular shape similarity [20] is often used to ﬁnd molecules with
similar shape, but different chemical structure, to an active tem-
plate (scaffold hopping). USR is a very fast shape similarity tech-
nique that has been successfully applied to the prospective
identiﬁcation of new inhibitors of a range of molecular and cell
targets [21e26]. A recent pharmacophoric extension of USR termed
UFSRAT [27] has also identiﬁed novel cell-active inhibitors of a type
II diabetes target in prospective virtual screens [28]. Other popular
ligand-based techniques include ROCS [29] for shape similarity and
MACCS ﬁngerprints [30] for chemical structure similarity. On the
other hand, when a known structural model of the target is avail-
able, docking techniques can also be used for structure-basedvirtual screening. Here we use AutoDock Vina [31], which is one of
the most accurate docking techniques. A molecular docking
approach using a PRL-3 homology model was already applied
previously leading to a rhodanine-based micromolar inhibitor of
PRL-3. The selectivity of this compound was, however, not exam-
ined [13].
In this study, we aimed at elucidating which prospective virtual
screening protocols are more suitable for this target while search-
ing for new cell-active PRL inhibitors. Due to its role in cancer
metastasis, we focused our computational screens on PRL-3.
Here we applied ligand-based USR, ROCS and MACCS ﬁnger-
prints to search the same chemical library for similar molecules to
thienopyridone. In addition, molecules with a similar shape to
thienopyridone were docked into two structural models of PRL-3
using Vina and the resulting scores were used to re-rank these
hits. Furthermore, a webserver implementing UFSRAT searches
over a second molecular library (see Section 4 for further details)
was also used to identify molecules with similar shape and phar-
macophoric properties as thienopyridone.
Using a biochemical screen we determined prospective hit rates
of the different methods for PRL-3, which suggest that ligand-based
screens are more suitable for PRL-3 hit identiﬁcation than
structure-based screens. In particular, USR led to the discovery of a
novel inhibitor chemotype for PRL-3, a 2-cyano-2-ene-ester. A
following structureeactivity-relationship (SAR) study based on this
compound revealed a low micromolar, noncompetitive inhibitor of
the PRLs with acceptable selectivity over other PTPs. The compound
is non-cytotoxic, active inside cells as indicated by its selective
reversion of the enhanced cell migration phenotype induced by the
PRLs, and commercially available. In contrast to thienopyridone
that showed to block cell proliferation independently of PRL-3, our
inhibitor can be applied to long-term cellular studies as it does not
show an effect on cell proliferation. Furthermore, ﬂuorescence
microscopy reveals its localization to the plasma membrane, which
can greatly reduce possible off-target effects due to its co-
localization with PRL-3. These properties make it currently the
only molecule for a broad use in PRL research.
2. Results and discussion
2.1. In silico screens and their biochemical evaluation
Ligand-based virtual screening requires at least one molecule
with afﬁnity for the target of interest. Herewe used thienopyridone
as a search template in all ligand-based runs because this molecule
is the most potent PRL-3 inhibitor to date [17] and has a rigid
chemical structure, the latter meaning that its lowest energy
conformer must be similar to its bioactive conformation. USR was
run to search a database with 641,485,760 conformers generated
from 3,472,461 lead-like molecules (see the Experimental section
for further details), which was completed in just 57 s using a sin-
gle computing core. ROCS required 128 h in screening the same
conformers using the same computer. Unlike USR and ROCS,
MACCS ﬁngerprints is a 2D technique and thus operates directly on
the chemical structures and therefore it does not require confor-
mational expansion. Thus, searching the 3,472,461 chemical
structures, encoded as the same number of MACCS ﬁngerprints, for
those with similar structure to thienopyridone took 24 s. At a sec-
ond stage, we also used the UFSRAT webserver with thienopyr-
idone as search template, which returned the top 200 molecules in
a couple of seconds.
In parallel, we explored the use of structure-based virtual
screens, although we were aware of the challenges that PRL-3
presents to this approach: the active site is extremely ﬂexible,
solvent-exposed and there are no X-ray structures available. We
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and the PRL-3 homology model of the sulfate-bound PRL-1 crys-
tal structure [11]. The apo NMR structure presents the active site in
an open conformation. The general acid loop containing the
aspartic acid residue is oriented away from the active site pocket,
suggesting a strong conformational rearrangement occurring upon
substrate binding [32]. This is further supported by a comparison of
the PRL-3 apo NMR structure with crystal structures (apo and
sulfate-bound) of PRL-1, where the apo and ligand-bound struc-
tures of PRL-1 adopt very similar conformations, whereas the apo
structure of PRL-3 shows signiﬁcant differences, adopting a much
wider and ﬂatter active site entry pocket [3]. Therefore, we thought
that these structural differences could be the basis for achieving
selectivity against other PRLs. For the ﬁrst docking run with Vina,
we assumed that thienopyridone was a competitive inhibitor and
thus we only docked those molecules with similar shape to thie-
nopyridone. The latter was done because similarly shaped mole-
cules tend to be complementary in shape to the same binding
pockets and thus should obtain higher hit rates than docking
randomly selected molecules. These docking runs were performed
against both the closed conformation (homology model) and the
open conformation (1v3a model) of PRL-3. Thus, we called these
runs docking1-hmod and docking1-1v3a, respectively. The second
docking run (docking2-1v3a) was carried on all the molecules, but
only against the open conformation, as this led to marginally better
results than the closed conformation in the ﬁrst docking run.
The screens USR, ROCS, MACCS, docking1-hmod and docking1-
1v3awere carried out ﬁrst. Selected compounds from these screens
were purchased and tested for inhibition against PRL-3 in an in vitro
phosphatase activity assay (see the Experimental section). Once the
results were available, we carried out the UFSRAT and docking2-
1v3a screens to investigate the impact of adding ligand-based
pharmacophoric constraints and docking molecules with any
shape, respectively. Inhibition was ﬁrst analyzed at a single com-
pound concentration. Active compounds in this screenwere further
evaluated for their respective IC50 values, and the hit rates for the
computational screens were based on these. Table 1 shows the hit
rates of these studies showing that overall, ligand-based similarity
screening approaches worked well on PRL-3 as enzyme target and
the used ligand thienopyridone.
The MACCS screen obtained the highest hit rate, but as expected
these hits had similar chemical structures to thienopyridone. USRTable 1
Summary of results for the applied virtual screeningmethods. The variousmolecular
similarity methods using the PRL-3 inhibitor thienopyridone [17] as a search tem-
plate are listed (the ﬁrst row refers to all ligand-based methods as a whole). Dock-
ings were performed with the PRL-3 docking models docking1-1v3a, docking1-
hmod and docking2-1v3a, as explained in the text. For the purpose of this study,
we regarded as a hit a tested compound with an IC50 value of about 100 mM or less
against PRL-3 using DiFMUP as substrate. The IC50 values of these ﬁve hits were 31,
48, 58, 102 and 108 mM (four additional inhibitors with potencies less than 200 mM
were found but not further considered as their IC50 value was deemed too high to be
promising for potential optimization). Hit rates are provided to quantify the per-
formance of each method on PRL-3.
In silico method Hit rate
(%)
# hits within tested
compounds
# tested
compounds
Similarity screens
(total)
12.2 5 41
USR 15.4 2 13
MACCS 28.6 2 7
UFSRAT 8.3 1 12
ROCS 0 0 9
Docking1-1v3a 0 0 9
Docking1-hmod 0 0 10
Docking2-1v3a 0 0 27obtained the second highest hit rate, with one of the two hits
exhibiting a very different chemical scaffold than thienopyridone.
ROCS used the same molecular database and query molecule than
MACCS and USR, but found no hits. UFSRAT, which used the same
query molecule but different screening database than the other
three ligand-based methods, obtained the third highest hit rate.
On the other hand, docking USR hits to re-rank them according
to the Vina score did not provide any hits regardless of the used
structural model. Later, we established that thienopyridone is not
competitive with DiFMUP as screening substrate (see Section 2.3),
which means that molecules similarly shaped to this query mole-
cule are not expected to be complementary in shape to any
conformation of the active site. This suggests that the reason why
structure-based screens did not ﬁnd any hits is that we are docking
against two conformations of the active site that are probably quite
different from its unknown bioactive conformation. Overall, we
observed that USR, UFSRAT and MACCS were useful for this target,
which is remarkable given the low number of tested compounds
required, thereby providing hits for a challenging target in a fast
and cheap manner. Thus, in our hand ligand-based techniques
seemmuchmore suitable than structure-based techniques for PRL-
3 hit identiﬁcation.
Out of the tested compounds from the in vitro evaluation of our
in silico approaches, compound 1, a 2-cyano-2-ene-ester, per-
formed the best (Fig. 1). Compared to thienopyridone itself, com-
pound 1 has quite different structural features, although being a top
hit of a shape similarity screen. Interestingly, compound 2 was the
only hit found in this screen that is structurally similar to thieno-
pyridone, the original ligand of our in silico approaches. The rho-
danine derivative [13] was furthermore chosen as additional
positive control for the following biochemical studies (Fig. 1).
Table 2 shows IC50 values of these structures against PRL-3 and
its close homologs PRL-2 and PRL-1. Compound 1 inhibited PRL-3
comparably well to the commercially available rhodanine control
with IC50s of around 50 mM in both cases. This control compound
was published with an IC50 of 13.3 mM against PRL-3 [13], which is
lower but in the range of the value obtained under the conditions
used here. Thienopyridone still remains the most potent PRL in-
hibitor published so far, with equal IC50s for all PRLs in the sub-
micromolar range that are comparable to the published values
[17]. Of note, as explained in the experimental section, thienopyr-
idone seemed to spontaneously induce substrate hydrolysis in ourFig. 1. Structures of compounds 1 and 2 from the USR shape similarity screen, as well
as of the two controls thienopyridone [17] and a rhodanine derivative (nr. 1 from Park
et al. [13]).
Table 2
IC50 values of thienopyridone, the rhodanine control and compounds 1 and 2 from in
silico screens, obtained by in vitro DiFMUP dephosphorylation (see the Experimental
section). ID of the ZINC database [33] and screening origin are indicated.
Compound IC50 [mM] Origin of hit ZINC-ID
PRL-3 PRL-2 PRL-1
Thienopyridone 0.24 ± 0.13 0.24 ± 0.00 0.26 ± 0.03 Positive
control [17]
Rhodanine 53 ± 10 27 ± 7 35 ± 14 Positive
control [13]
970452
1 48 ± 13 104 ± 15 70 ± 20 USR screen 6947664
2 102 ± 26 188 ± 39 209 ± 81 USR screen 20347422
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obtained by this substrateeinhibitor combination should be taken
with care. Nevertheless, since the original publication provided
similar IC50 data obtained by a different assay setup in combination
with a different substrate [17], we consider our result as condi-
tionally correct. Compound 2 as thienopyridone-analog showed
only minor activity against PRL-3. Since compound 1 was the most
potent one found in this screen, it was chosen as starting point for
follow-up studies.
2.2. Structureeactivity relationship study for compound 1
In order to optimize the inhibitory potential of compound 1 and
to understand which residues are important for the activity, 23
close structural analogs were purchased and analyzed for inhibition
against the PRL family members (Fig. 2, see also Supplementary
Figure S1). This SAR study showed that a substitution is well
tolerated in certain positions, whereas it is not at all tolerated in
others. Fig. 3 highlights these ﬁndings by summarizing all changes
and their outcomes in activity retention or loss. Exchanging the
isomeric conformation from E to Z led to a weakened activity of the
compound. Furthermore, exchanging the residues attached to the
ester moiety generally diminished the inhibitory potency. Amides
instead of esters were not tolerated at all, as well as any substitution
in positions 4 or 6 of the aromatic ring. Addition of a methoxy-
group in position 3 was well tolerated, as well as exchanging this
moiety by bromine. In position 2 apparently only a hydroxyl group
is accepted, because changing the features at this position led to
weakening or loss of potency in all other cases. Analog 3 showed an
increase in potency against all three PRL enzymes and represents
the most potent analog with an IC50 of 31 mM against PRL-3, sur-
passing the potency of the rhodanine control toward PRL-3 in our
measurements.
2.3. Further in vitro evaluation of inhibition
In order to exclude the possibility of false-positive inhibition by
aggregation-based mechanisms, solubility in assay buffer was
ensured for all active hits by measuring and excluding light-
scattering abilities in the used concentration ranges
(Supplementary Table S1). Moreover, all hits and controls were
shown to be reversible inhibitors by time-dependent assaying of
enzyme-inhibition [34]. Compounds showed the same level of in-
hibition when incubated with enzyme for different time periods
(data not shown). In addition, all hits and controls were tested for
the possibility of being redox-cycling compounds and therefore
leading to false-positive readouts due to generation of
phosphatase-inhibiting hydrogen peroxide [35]. To this end, the
compounds in assay buffer were treated with 1 mM catalase for
10 min prior to addition of enzyme and substrate, in order to
consume any hydrogen peroxide possibly being generated. None ofthe compounds showed loss of activity when assayed in the pres-
ence of catalase (data not shown), and we conclude therefore that
all compounds are true-positive PRL inhibitors in vitro. Since all
compounds were purchased, we ensured their purity by analyzing
all active compounds by UPLC-MS. According to these measure-
ments, all active compounds were over 92% pure (Supplementary
Table S2).
The type of inhibition was analyzed for analog 3 as our best hit
and, additionally, for thienopyridone, since no such data was pub-
lished for this compound [17]. We performed detailed kinetic an-
alyses on analog 3 inhibiting DiFMUP hydrolysis by PRL-3. Our data
showed clear noncompetitive behavior for this compound
(Supplementary Figure S2). We furthermore plotted IC50 values
against various used DiFMUP concentrations, showing that both
compounds act noncompetitively against DiFMUP as substrate,
since the obtained IC50s did not change with altered DiFMUP con-
centration [36] (Supplementary Figure S2B). Our results indicate
that both noncompetitive inhibitors interact with the enzyme at a
site different than the DiFMUP interaction site, and that this
interaction is independent of binding of the substrate to the
enzyme itself. Importantly, this behavior reﬂects the reaction of
PRL-3 with DiFMUP, a non-natural phosphorylated substrate for
which the exact interaction residues with the enzyme are unknown
except of the catalytically active residue Cys104. Hence, we can
conclude that the inhibitors interact with PRL-3-residues different
from the ones used for binding DiFMUP.
2.4. Molecular docking of compound 1, analog 3 and
thienopyridone
Taking into account the very ﬂexible apo structure of PRL-3 in an
open conformation with the catalytic residues Cys104 and Asp72
positioned at different loop regions pointing away from each other
[32], the noncompetitive behavior of analog 3 and thienopyridone
with DiFMUP as reaction substrate can be rationalized by the
increased possibility of interaction sites of inhibitor and enzyme
before molecular rearrangement into a closed substrate-converting
state takes place.
We performed molecular docking on the open PRL-3 structure
with analog 3, its parent molecule from the in silico screen (com-
pound 1) and thienopyridone, in order to further evaluate this
result. Fig. 4 shows the respective top 5 binding poses of the
respective inhibitor docked to PRL-3 (pdb entry 1V3A) with the two
catalytic residues indicated. Comparing the docking result of all
three inhibitors, they all bind in a similar region close to the cata-
lytic Asp72, suggesting a possible interaction with this residue.
Notably, no interaction is seen with Cys104, the catalytic residue
important for binding to the phosphate substrate. This is in
agreement with the result of our inhibitor-type study, showing that
the inhibitors bind independently of the DiFMUP substrate (which
indispensably interacts with residue Cys104). In all top poses,
analog 3 and compound 1 bind in a very similar manner, with the
hydroxyl group pointing either towards Asp72 or alternatively
downwards to a patch with a glutamine and an asparagine residue
in close proximity. Since this hydroxyl group is crucial for inhibition
due to complete loss of potency when substituted by other moi-
eties, we suggest that a hydrogen bond may be formed either with
Asp72, or with glutamine or asparagine when positioned down-
wards. Nevertheless, the remaining conclusions of the SAR study
cannot be rationalized by the docking results. The same is the case
for thienopyridone. In general, docking scores were remarkably low
as a result of a ﬂexible protein structure and low-molecular-weight
ligands. Therefore, these docking results can only give a rough
estimation of the possible binding region of the inhibitors. Without
a co-crystal structure of enzyme and ligand, this remains
Fig. 2. Structures and respective activities of all tested analogs from the SAR study of compound 1. IC50 values (mM) for inhibition of DiFMUP dephosphorylation are shown for PRL-
3, PRL-2 and PRL-1, where applicable.
O
O
Br
HO
N
21
Fig. 3. Result of the SAR study after analyzing 23 analogs of compound 1. Green e
substitution tolerated; blue e substitution weakens potency; red e substitution leads
to loss of activity. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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enzyme would spare room for further modiﬁcations of the ligands
by more elaborate SAR studies.Fig. 4. Molecular docking of inhibitors into the open PRL-3 structure (pdb entry 1V3A), wit
poses are shown. From left to right: analog 3 e compound 1 e thienopyridone.2.5. Selectivity of hits over other phosphatases
In order to evaluate our compounds' abilities to inhibit other
phosphatases, selectivity tests were carried out by in vitro inhibi-
tion assays against the protein tyrosine phosphatases PTP1B and
TCPTP as well as the unrelated dual-speciﬁcity phosphatase VHR.
Compounds were assayed at a concentration roughly around their
IC50 values (50 mM in all cases expect of thienopyridone, which was
assayed at 0.5 mM concentration) and activities were compared
between PRL-3 and the above-mentioned phosphatases. All en-
zymes were measured at their respective KM values towards
DiFMUP (see the Experimental section). Table 3 shows a summary
of these data, depicted by a selectivity index (see also
Supplementary Figure S3). Compound 3 as our best analog showed
higher selectivity towards PRL-3 compared to the other phospha-
tases, but not as good as thienopyridone. Compound 1 showed
acceptable selectivity only over VHR. Notably, the rhodanine con-
trol performed not well in this context. This was not studied in theh labeled catalytic residues Cys104 and Asp72. For each inhibitor, the top ﬁve docking
Table 3
Selectivity of compounds towards PRL-3 over other phosphatases. DiFMUP
dephosphorylation was measured at the respective KM of each enzyme, at a com-
pound concentration of 50 mM (thienopyridone: 0.5 mM) and enzyme concentration
of 35 nM. Selectivity index ¼ 1 e (inhibition of PRL-3/inhibition of enzyme). The
closer the value is to 1, the higher the selectivity towards PRL-3.
Compound Selectivity index towards PRL-3 over
PTP1B TCPTP VHR
Thienopyridone 0.93 0.93 0.93
Rhodanine control 0.34 0.22 0.54
1 0.38 0.46 0.64
2 0.25 0.10 0.25
3 0.65 0.77 0.85
4 0.08 0.29 0.24
5 0.48 0.24 0.44
B. Hoeger et al. / European Journal of Medicinal Chemistry 88 (2014) 89e10094original publication [13], but given the known inherent properties
of rhodanines as promiscuous binders [37], this ﬁnding is not
surprising.
2.6. Cytotoxicity and in-cell efﬁcacy of the new inhibitors
For determination of short-term cytotoxic effects of active hits
on mammalian cells, the HEK293 cell lines were incubated with
compounds or DMSO vehicle for 16 h. Surviving cells were stained
by MTT labeling. The results are shown in Fig. 5 for PRL-3 and
empty vector control cell lines, as well as in Supplementary
Figure S4 for PRL-1 and PRL-2. Only analog 5 showed a strong
cytotoxic effect compared to the DMSO vehicle in all cell lines. A
signiﬁcant, but weak cytotoxic effect could also be seen with
compound 1 at 75 mMconcentration in the case of the empty vector
control. Overallewith the exception of named analog 5e all tested
hits show no signiﬁcant cytotoxic effects under these conditions,
including thienopyridone and the rhodanine control.
PRL-3's ability to enhance cell migration and invasion has been
shown in various studies [3]. We therefore tested our newly
discovered inhibitor 3 in comparison to the control compounds for
reversion of PRL-3 induced cell migration by a transwell migration
assay in HEK293 cell lines stably expressing PRL-3 or the empty
vector control. Analog 3 was tested at three different concentra-
tions, with 75 mM as the highest one that has been shown to be
non-cytotoxic (see above). The rhodanine control was tested at
75 mM. Thienopyridone was used at 20 mM due to its higher
in vitro potency [17]. As the results in Fig. 6A show, treatment of
PRL-3-expressing cells with 75 mM analog 3 and the thienopyr-
idone control signiﬁcantly reverted cell migration to the basal
level of the empty vector cells. Reduced migration could as well be
observed in samples treated with 50 mM analog 3, but not with
12 mM. Hence, analog 3 shows concentration-dependent inhibition
of PRL-3 induced cell migration. The rhodanine control showed
only a negligible effect suggesting that this compound is either
poorly cell-permeable, metabolized inside cells, or not selectively
inhibiting PRL-3 in a cellular context, as already suggested by our
in vitro selectivity study. Importantly, analog 3 as well as thieno-
pyridone did not show a signiﬁcant reduction of migration of the
control cells, indicating that their action under these conditions is
PRL-3-speciﬁc (Fig. 6B).
In the absence of clear physiological substrates as read-outs to
show the ability of analog 3 to speciﬁcally inhibit PRL-3 inside cells
[3], the inhibition migration of PRL expressing cells was further-
more demonstrated by microscopic means. To this end, wound
healing experiments were carried out over 20 h with PRL and
empty vector control cell lines by comparison of treatment with
varying concentrations of compound or DMSO vehicle. Pictures of
the proceeding wound closure were taken at the indicated timepoints, as summarized and quantiﬁed for PRL-3 in Fig. 7, and
quantiﬁed for PRL-2 and PRL-1 in Supplementary Figure S5. In
agreement with the results of the transwell migration experiment,
a complete inhibition of PRL-3 induced cell migration to the
respective basal level of the control cell line could be observed in
the presence of 50 mM as well as 35 mM analog 3. A slight delay of
gap closure was still visible with 25 mM analog 3. The effect was
diminished with treatment of 12 mM compound concentration, as
in the transwell assay. The inhibitor had no effect on migration of
the empty vector control cells (Fig. 7). We conclude that analog 3
speciﬁcally inhibits migration of PRL-3 expressing cells in a
concentration-dependent manner. The compound is also able to
inhibit migration of PRL-2 and PRL-1 expressing cells at 50 mM
concentration, however in the case of PRL-2 not as efﬁciently as
with PRL-3 and PRL-1 (Supplementary Figure S5).
As control experiment, similar wound healing experiments
were carried out with varying concentrations of thienopyridone.
The inhibitor was reported to fully inhibit HUVEC cell migration at a
concentration of about 15 mM [17]. Here, thienopyridone fully
inhibited migration of PRL-3 expressing HEK293 cells at a con-
centration of about 20 mM (Supplementary Figure S6). This is in
good agreement with the published result and close to the effective
concentration of analog 3 (35 mM). When comparing the effective
cellular concentrations of thienopyridone and analog 3 taking into
consideration their IC50 values in vitro (0.2 versus 31 mM for thie-
nopyridone and analog 3, respectively), it becomes clear that
analog 3 shows similar potencies in cells as in the in vitro experi-
ments whereas thienopyridone does not. This could indicate that
thienopyridone might be degraded, does not enter cells efﬁciently
or has other targets and effects inside cells.
In order to rule out any cell-proliferative side effects of PRL-3
overexpressing cells that could inﬂuence time needed for the gap
closure, we conducted a proliferation experiment on both PRL-3
and control HEK293 cell lines. Both cell lines show similar pro-
liferation proﬁles (Supplementary Figure S7), conﬁrming the
unbiased basis for the comparative migration studies. Further-
more, we analyzed the effect of our tested inhibitors on cell
proliferation of PRL-3 overexpressing or empty vector control
HEK293 cells. Compounds that interfere with the cell prolifera-
tion machinery could potentially also inﬂuence the cell's migra-
tion abilities. In order to exclude such indirect effects, we
conducted cell proliferation experiments on PRL-3 and control
cell lines in the absence or presence of analog 3 or thienopyr-
idone. Fig. 8 summarizes these results, showing that analog 3 had
no signiﬁcant inﬂuence on HEK293 cell proliferation, whether or
not PRL-3 is overexpressed. Thienopyridone, on the other hand,
severely inﬂuenced cell proliferation potentially by blocking cell
cycle progression, which we reason because we did not observe a
short-term (within one cell cycle) cytotoxicity of the compound
(Fig. 5). Importantly, this anti-proliferative effect is entirely in-
dependent of PRL-3, since the compound had the same effect on
the empty vector control cells (Fig. 8). Thus, thienopyridone
showed strong cellular effects that cannot be attributed to its
activity toward PRL-3. We cannot conﬁdently conclude if this
effect plays a causative role in the observed inhibition of cell
migration. However, this result strongly suggests that biological
experiments carried out with thienopyridone should be inter-
preted with caution.
Finally, we tested the inhibitors' suitability for cellular applica-
tions in ﬂuorescence microscopy by monitoring mKate-PRL-3 and
GFP constructs on a confocal microscope in the presence and
absence of inhibitor. We observed that the presence of analog 3 did
not inﬂuence the ﬂuorescence readouts of mKate-PRL-3 and GFP
(Fig. 9a and b), indicating that the compound is suitable for such
imaging applications. Thienopyridone, on the other hand, showed a
Fig. 5. Cytotoxicity of compounds with PRL-3 expressing (A) or empty vector (B) HEK293 cell lines. After 16 h incubation, surviving cells are stained with MTT and absorbance is
normalized to DMSO vehicle. Results are depicted as mean ± SD, with compounds color-coded and concentrations as indicated. Two-sided t-tests were performed for p < 0.05,
compared to DMSO vehicle. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Effect of compounds on transwell cell migration. A) PRL-3 expressing (black) or empty vector control (gray) HEK293 cell lines were seeded into transwell insert chambers in
the presence of compound or DMSO vehicle and allowed to migrate for 16 h (see the Experimental section). Cells that had migrated to the lower compartment were dissociated and
stained with calcein-AM for ﬂuorescence readout on a multiwell plate reader. Compound concentrations and the number of data points (N) are indicated. Results are depicted as
mean ± SD, normalized to the empty vector signal. Two-sided t-tests were performed for p < 0.05. ns e not signiﬁcant. B) Respective control experiment with empty vector cell line.
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(Fig. 9c and d). The compound is therefore not useful for micro-
scopy experiments, at least when using green and red ﬂuorescent
proteins. Interestingly, analog 3 showed auto-ﬂuorescence when
excited at 405 nm and viewed at about 450 nm that does not
interfere with green or red channels. Surprisingly, the compound
localized to the plasma membrane and to a lesser extent to inner
membrane compartments (Fig. 9a and b), apparently co-localizing
with its target PRLs. This is the case both in cells overexpressing
(mKate-PRL-3 construct) and lacking (GFP construct) PRL-3, indi-
cating that the inhibitor's localization is a structure-inherent
feature. In order to test this further, we investigated the localiza-
tion of analog 7, which is equally ﬂuorescent when excited at
405 nm. The analog was inactive in vitro and did not affect wound
healing abilities of PRL-3 expressing cells (Supplementary
Figure S8) Like analog 3, this compound localized to the plasma
membrane and inner membrane compartments, although showing
a slightly bigger proportion of vesicular localization (Fig. 9e and f).
This suggests that the structure rather than the activity determines
the compounds' localization. The co-localization of analog 3 with
PRL-3 at the plasmamembrane could explain the inhibitor's equally
strong cellular potency compared to its in vitro activity.We consider
this localization advantageous for any cellular studies targeting PRL
proteins, since co-localization of both enzyme and inhibitor should
greatly reduce any off-target effects.3. Conclusion
In the computational part of this study, we applied a number of
virtual screening techniques in order to elucidate which is the
most suitable for applying it on a larger scale for PRL-3 as target.
This only required testing a total of 87 compounds, which is far
cheaper and quicker than screening a much larger library of
randomly selected compounds. Importantly, most of these hits
contain new PRL-3-active scaffolds with the focused compound of
this study being a 2-cyano-2-ene-ester, produced by the USR
screening method. As the most suitable virtual screening methods
for this target have obtained hit rates in the range of 16e22%, we
expect that exclusively using these on much larger molecular
databases using several diverse PRL-3 inhibitors as templates will
lead to many more additional inhibitors. The latter is necessary to
build accurate QSAR models for each member of the PRL family as
a way to ultimately search for selective and potent PRL-3
inhibitors.
Testing a further 23 purchasable analogs of our preliminary hit
has led to a low micromolar, noncompetitive PRL inhibitor that is
quite selective over other PTPs compared to a published rhodanine
inhibitor with similar potency [13], but not as good as the potent
PRL inhibitor thienopyridone [17]. Rhodanines are compounds that
are considered PAINS e so-called frequent hitters with promiscu-
ous binding properties [37] e and should be used with caution. Of
Fig. 7. Analog 3 inhibits PRL-3 induced cell migration. Wound healing abilities of PRL-3 expressing or empty vector control HEK293 cell lines were analyzed in the presence of
analog 3 or DMSO vehicle. A) Pictures of the wound gaps were taken at 0 h and 20 h time points for each condition, as indicated. a) DMSO vehicle, b) 50 mM analog 3, c) DMSO
vehicle, d) 50 mM analog 3, e) 35 mM analog 3, f) 12 mM analog 3. B) Quantiﬁcation of the wound healing experiment. PRL-3 data are shown in black, empty vector data in gray. Speed
of migration is shown for combined data, as mean ± SD. Two-sided t-tests were performed for p < 0.05. ns e not signiﬁcant.
Fig. 8. Proliferation experiment of PRL-3 expressing (A) and empty vector control (B) HEK293 cell lines with analog 3 and thienopyridone. Respective cells were seeded in equal
numbers into a 96-well plate on day 1 and incubated with the respective compound or DMSO vehicle, as explained in the Experimental Section. Live cells were stained with MTT
and analyzed on a plate reader every indicated day.
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Fig. 9. Confocal ﬂuorescence microscopy of compounds with mKate-PRL-3 or GFP transfected HEK293 cells, as indicated, after 30 min incubation. The distribution did not change
after 1.5 h (measured with analog 3 only, data not shown). For thienopyridone and mKate-PRL-3 (d), a PRL-3 high-expressing example was chosen for presentation in order to
ensure a visible difference to the thineopyridone signal. Compounds were visualized by exciting at 405 nm. GFP was excited at 488 nm, mKate at 561 nm. Scale bar ¼ 10 mm.
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not sufﬁciently active inside cells to modify the studied pheno-
types, even at high concentration.
We showed that our developed inhibitor (analog 3) is non-
cytotoxic and able to efﬁciently inhibit the PRLs inside cells. It re-
verts PRL-3-induced cell migration back to basal levels in a
concentration-dependent manner, and it is furthermore able to
inhibit PRL-1 and PRL-2 activity inside cells. The compound exerts
full cellular activity against PRL-3 at a concentration of around
35 mM, which is similar to its in vitro potency of 31 mM, and similar
to the in-cell active concentration of thienopyridone. Furthermore,
analog 3 unexpectedly showed localization to the plasma mem-
brane, independently of PRL-3 overexpression. As PRL-3 localizes to
the plasma membrane as well, this feature potentially minimizes
off-target effects that could occur in other cellular compartments
and likely represents the reason for the inhibitor's comparable
potency in cells and in vitro.
An interesting ﬁnding of our study is that thienopyridone
entirely blocks proliferation of HEK293 cells without being short-
term cytotoxic. This is a strong side effect of the compound that is
clearly independent of the expression of PRL-3. Consequently, this
behavior could inﬂuence the cells' migration abilities and may lead
to false positive inhibition in wound healing experiments, and
studies of molecular mechanisms of PRLs with thienopyridone
should be viewed with caution. In the original publication, the
authors demonstrate that thienopyridone induces anoikis in can-
cer cells, a type of apoptosis initiated by cleavage of p130Cas, and
that there is a functional link between the PRLs and p130Cas. They
could not observe p130Cas cleavage after PRL knockdown, and a
clear link between the observed phenotypes after thienopyridone
treatment and knockdown of the PRLs could not be made [17].
Overall, while thienopyridone clearly is a highly potent inhibitor of
PRL activity, this suggests that thienopyridone has also an inﬂu-
ence on the cells' apoptotic and proliferative machinery that does
not involve PRL activity. By contrast, our compound does not affect
cell proliferation and survival and therefore constitutes the only
PRL inhibitor developed to date that is active inside cells with no
obvious long-term side effects. Nevertheless, thienopyridone as a
strong PRL inhibitor was the starting point of our study, showing
the value of potent known inhibitors for computational ligand-
based studies.Potency and selectivity of our inhibitor within the class of PRL
enzymes could potentially be improved by conducting more elab-
orative SAR studies. To this end, a combination of chemical and
computational approaches as well as co-crystal structures would be
desirable. With its physicochemical properties and a clogP value of
about 2.5, our compound 3 follows Lipinski's rule of ﬁve [38]. Since
optimization tends to increase themolecular weight and logP, there
is scope for more comprehensive SAR studies to optimize its
selectivity and potency. Interestingly, the inhibitor shares very
similar structural features with Entacapone, an approved anti-
Parkinson drug [39], although the latter does not inhibit PRL ac-
tivity (data not shown). As molecules with similar chemical struc-
ture tend to have a similar pharmacology, our PRL-3 inhibitor and
its future optimized derivatives might be as safe as Entacapone
when administered in humans, which increases its therapeutic
potential.
Overall, we show here that ligand-based computational ap-
proaches work well with the target PRL-3 and its strong inhibitor
thienopyridone, as opposed to structure-based techniques.
Biochemical screening of only a modest number of compounds led
us to a micromolar inhibitor that we could further optimize by a
basic SAR study. The obtained molecule shows a remarkable in-cell
efﬁcacy by speciﬁcally inhibiting PRL-3 induced cell migration in a
dose-dependent manner, with similar effects on PRL-1 and PRL-2. It
is acceptably selective over other tested PTPs, does not disturb cell
proliferation, can successfully be applied to ﬂuorescence micro-
scopy and is commercially available.4. Experimental section
4.1. Materials
6,8-Diﬂuoro-4-methylumbelliferyl phosphate (DiFMUP) was
purchased from Life Technologies. 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was from Sigma. Thieno-
pyridone was purchased from Enamine by synthesis-on-demand.
Entacapone was a kind gift from Christian Klein, Heidelberg Uni-
versity. Tested compounds from in silico screens were from
Enamine and Vitas-M. Speciﬁcally, compound 1 and analog 3 were
from Enamine and the rhodanine control was from Vitas-M. All
other chemicals were purchased from Sigma and Merck.
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The main screening library was downloaded from the ZINC
database version 8 [33], more concretely subset 1 of all usual lead-
like ligands containing 3,472,461 molecules in MDL SD format. OE
omega 2.4.3 was runwith default settings on this set to generate an
average of 185 3D conformers per molecule, resulting in a molec-
ular database with 641,485,760 conformers (total CPU time was 15
days). USR descriptors were pre-calculated for each of the 641
million conformers, taking a total of 48 min on a single computing
core. MACCS ﬁngerprints were also precalculated with OpenBabel
2.3.1 (4.3 h for 3,472,461 molecules). The following similarity
thresholds were used: 0.95 (USR score), 0.9 (ROCS shape tanimoto
score) and 0.8 (MACCS tanimoto score) leading to 693, 23 and 30
highlighted molecules respectively. UFSRAT is available as a web-
server [40] and thus it screened a different multi-conformer data-
base of commercially available molecules (19,412,000 conformers,
with an average of four conformers per molecule). UFSRAT returns
the top 200 molecules in a couple of seconds.
Regarding docking, two structural models of PRL-3 were used.
The homology model is fully described in McParland et al. [11].
Python scripts from AutoDockTools (ADT) 1.5.4 were used to pro-
tonate the 1v3a model and database molecules at pH ¼ 7.4 as well
as converting them to pdbqt format. For each structure, the center
of the binding pocket was manually selected with the ADT GUI and
a cube with size 24 Å in each dimension set. Vina was run with
default exhaustiveness.
Each supplier catalog only covers part of the ZINC database. We
selected the two vendors with the best coverage of our hits
(Enamine and Vitas-M) to purchase compounds for in vitro tests. In
other words, we did not select every vendor so as to minimize
shipping costs. This means that not all high-ranking compounds
were tested. Furthermore, some of the ordered compounds turned
out to be unavailable, which again resulted in more high-ranking
compounds not being tested. However, this is not an issue as our
goal was not to be exhaustive, but rather to implement a fast and
very cost-effective protocol leading to new PRL-3 inhibitors.
4.3. Recombinant proteins
VHR, PTP1B and TCPTP were prepared as previously described
[41]. PRL-3, as well as PRL-1 and PRL-2, were prepared as in
McParland et al. [11], with the following modiﬁcations: Plasmid
vector pETM-20 was used to overexpress His-TEV-tagged fusion
proteins. After lysing and purifying His-tagged proteins accordingly
using a FPLC Histras HP 1mL column, His-tags were cleaved by His-
TEV protease and cleared by another round of Histrap column
chromatography.
4.4. In vitro phosphatase activity assay
In vitro evaluation of phosphatase and einhibitor activity was
determined using DiFMUP as ﬂuorogenic phosphate-substrate.
Recombinant PRL protein (35 nM ﬁnal assaying concentration)
was incubated in assay buffer (20 mM Tris-Cl, pH 7.5, 150 mMNaCl,
10 mM DTT, 0.01% Triton-X 100, 5% DMSO) for about 20 min before
proceeding, in order to ensure full reduction and thereforemaximal
activity.
KM values were determined by measuring reaction kinetics of
substrate dilution series on a 96-well plate reader (excitation
358 nm, emission 452 nm). Initial velocities were plotted against
DiFMUP concentration and the data was analyzed by Michae-
liseMenten kinetics curve ﬁtting using GraphPad Prism 6.
Enzyme inhibition was determined at a substrate concentration
corresponding to the respective KM value of the individual enzyme(21 mM for PRL-3; 24 mM for PRL-1, PRL-2, PTP1B and TCPTP; 90 mM
for VHR). PTP1B and TCPTP were assayed in a buffer described by
Meyer et al. [40]. IC50 data were obtained by measuring inhibitor
concentration series. After baseline correction (respective inhibitor
in the absence of enzyme), initial velocities were plotted against
inhibitor concentration (logarithmic scale) and analyzed with
GraphPad Prism 6.
When measuring PRL-inhibition with thienopyridone, we
observed spontaneous DiFMUP hydrolysis in the presence of high
concentrations of inhibitor (and the absence of enzyme) leading to
the blank-subtracted data curves showing a potentially false posi-
tive “full inhibition”. This effect could not be seen at inhibitor
concentrations below 2 mM. Although measuring concentrations
around the IC50 value (0.2 mM) was apparently acceptable, we
consider this behavior as unusual and this could lead to a false IC50
value measured by our method. Nevertheless, in the original pub-
lication the measurement of the IC50 value for thienopyridone was
carried out using a different assay setup including a different sub-
strate, and our IC50 value matches the published ones [17]. There-
fore our measured value should be accurate in spite of the unusual
behavior at high inhibitor concentration.4.5. Solubility and purity of compounds
Solubility of compounds in assay buffer (see corresponding
paragraph) was measured in the same concentration range as used
for IC50 determination. Light scattering was measured on a Neph-
eloStar (BMG Labtech) in comparison to a buffer blank.
Purity of hits was validated by UPLC-MS on a Waters Acquity
System with a ACQUITY UPLC BEH C18 Column and a gradient of
5e100% acetonitrile containing 0.2% formic acid. Absorbance was
detected between 210 and 400 nm by a PDA detector. Peak areas
were integrated from signals at 254 nm.4.6. Cell culture and generation of stable cell lines
HEK Flp-In T-rex 293 cells (Invitrogen) were grown in Dulbec-
co's modiﬁed Eagle's medium (DMEM) supplemented with 10% FBS
(Invitrogen), 1% L-glutamine, 1% penicillin and 1% streptomycin in a
humidiﬁed atmosphere containing 5% CO2.
Cell lines containing stably integrated human PRL-3, PRL-2, PRL-
1 or the respective empty vector construct were prepared as pre-
viously described [11]. Stable cell lines were grown in selection
medium (supplemented with 15 mg/mL blasticidin and 100 mg/mL
hygromycin). Protein expression was induced by addition of tetra-
cycline (1 mg/mL) 20 h prior to performing follow-up experiments.4.7. Cytotoxicity assay
Tetracycline-induced HEK293 stable cell lines were seeded in a
transparent 96-well platewith 10000 cells/well in growthmedium.
After 24 h incubation, compounds and DMSO controls were added
to the respective wells in the indicated ﬁnal concentrations and
incubated for 16 h. The medium was removed, fresh medium was
added to each well, MTT (5 mg/mL in PBS; used 1:10 in growth
medium) was added and the cells were further incubated for 4 h at
37 C. Finally, the medium was removed, 100 mL DMSO was added
to each well, pipetted thoroughly to dissolve the produced for-
mazan crystals, and incubated 10 min at RT. Absorbance was
determined at 570 nm in a multiwell plate reader and the data was
normalized to the respective DMSO vehicle. Each measurement
was carried out in triplicates in at least two independent
experiments.
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HEK293 stable cell lines were seeded in a transparent 96-well
plate with 1500 cells/well in growth medium supplemented with
tetracycline and grown for the indicated time. For experiments
containing inhibitors, respective compounds or DMSO vehicle were
added immediately after seeding. Analog 3 was used at 50 mM,
thienopyridone at 20 mM concentration. At each indicated day, the
medium was removed from the respective wells and MTT was
added like described above. After 4 h incubation at 37 C, 100 mL
DMSO was added into the respective wells and absorbance was
read at 570 nm. The measurement was performed in triplicates.
4.9. Transwell migration assay
HEK293 stable cell lines were induced with tetracycline 20 h
prior to seeding into transwell inserts. Cells were starved for 6 h
and washed twice with serum-free growth medium. Cells
(5e10  105 per well) were seeded into the upper chambers of 24-
well transwell inserts (100 mL, 8 mm membrane pore size; Brand)
and supplemented with the respective inhibitor or DMSO control.
The lower chambers were ﬁlled with 800 mL growth medium
containing 5% FBS. Migration was allowed for 16 h at 37 C. Insert-
membranes were washed once by carefully dipping into PBS. The
medium was removed from the lower chamber. Inserts were
returned to the respective compartment and 700 mL of Cell Disso-
ciation Solution (amsbio) containing 1.2 mL/mL Calcein-AM
(1.67 mg/mL in DMSO; Life Technologies) was added. Dissociation
and staining was allowed for 1 h at 37 C. 100 mL solution of each
well was pipetted into a black 96-well plate (in triplicates per trans-
well) and stained cells were analyzed on a multiwell plate reader
(excitation 485 nm, emission 520 nm). The experiment was carried
out repeatedly in four replicates per condition. The number of in-
dividual data points is indicated in the results section.
4.10. Wound healing assay
Wound healing experiments were carried out with m-dish
35 mm culture inserts from Ibidi. 9  105 cells/mL of the respective
HEK293 stable cell lines were seeded into each of the two insert
wells and allowed to settle for 20 h in the presence of tetracycline.
On the day of experimentation the inserts were gently removed
and growth medium supplemented with 5% FBS and the respective
compound or DMSO vehicle were added. Pictures of the wound gap
were taken at 0 h and 20 h time points. A Zeiss Cellobserver HS
microscope was used with 10 magnitude.
4.11. Confocal microscopy
HEK293 cells were transfected with 0.1 mg of mKate-PRL-3 or
GFP constructs 18 h before imaging on a Leica SP2 confocal mi-
croscope equipped with a 63 oil lense. Compounds were added in
imaging buffer (50 mM analog 3 and analog 7, 20 mM thienopyr-
idone) and incubated for 30 min before imaging. The following
imaging buffer was used: 20 mM HEPES, pH 7.4, 115 mM NaCl,
1.2 mM CaCl2, 1.2 mMMgCl2, 1.2 mM K2HPO4. GFP was excited with
a 488 nm laser, mKate with a 561 nm laser. Compounds were
visualized with a 405 nm laser.
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